Back to results
US 5,211,937 AGranted
Method of determining a site of inflammation utilizing ELAM-1 ligands
AssigneeGlycomed Incorporated
InventorsBrian K. Brandley, Michael Tiemeyer, Stuart J. Swiedler, Margaret Moreland, Hans Schweingruber
Life of this patent
Estimating the term…
Abstract
Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation.
Claims5
A method of determining a site of inflammation in a patient, comprising the steps of:
- injecting into the patient's circulatory system an injectable formulation comprising an effective amount of an ELAM-1 ligand attached to a detectable label wherein the ELAM-1 ligand is selected from the group consisting of NeuAc (.alpha.2,3)Gal(.beta.1,3)[Fuc(.alpha.1,4)]GlcNAc and structural isomers thereof which bind to the same degree or more to ELAM-1;
- allowing the labeled ELAM-1 ligand sufficient time to circulate in the patient and attached to ELAM-1 in the patient;
- and
- detecting the label and its location in the patient and thereby determining the site of inflammation.
1 more element
Dependencies are inferred from the claim text.